http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2667521-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_28cecfc87bfdb41e74447f4815647949 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3cde10605b30794fd676f517ea84dddf |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-90245 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57419 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-485 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2007-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7c5aa528722dba9a523bb916bab8798 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_54f368aed3757022f45c839743b7829c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_feac8f093d52ea73387fe07fc4a743e7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44c353052bc23fc7289a4a673d760433 |
| publicationDate | 2008-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2667521-A1 |
| titleOfInvention | Assay for metastatic colorectal cancer |
| abstract | This invention relates, e.g., to a method for predicting the prognosis, t he likelihood of metastasis in, or the desirability of administering an aggr essive therapy to, a subject with colorectal cancer, comprising determining, in a sample from the subject, the level of phosphorylation compared to a po sitive and/or negative reference standard, of one or more of: (a) AKT (S473) ; (b) BAD (S l 12); (c) cABL (T735); (d) ERK (T42/44); (e) MARCKS (S 152- 15 6); (0 p38MAPK (T l 80- 182): (g) STAT l (Y701 ); (h) PTEN (S380); (i) EGFR (Y992); (j) PAK 1 /2 (S l 19/204); or (k) PKC zeta/lambda (T410-403); or the total amount of (1) COX-2 protein; wherein if the level of phosphorylation of one or more of a-i or the total amount of COX-2 protein (1) is elevated c ompared to the negative reference standard, and/or i f the level of phosphor ylation of j or k is decreased compared to the positive reference standard, the subject has poor prognosis, is likely to undergo metastasis, and/or is a good candidate for aggressive therapy. Also described are methods for treat ing subjects likely to develop metastatic colorectal carcinoma, and pharmace utical compositions and kits for implementing methods of the invention.</SDO AB> |
| priorityDate | 2006-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 202.